In Re Jack Emert and Robert D. Lundberg

124 F.3d 1458, 44 U.S.P.Q. 2d (BNA) 1149, 1997 U.S. App. LEXIS 25270, 1997 WL 576504
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 18, 1997
Docket96-1559
StatusPublished
Cited by23 cases

This text of 124 F.3d 1458 (In Re Jack Emert and Robert D. Lundberg) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Jack Emert and Robert D. Lundberg, 124 F.3d 1458, 44 U.S.P.Q. 2d (BNA) 1149, 1997 U.S. App. LEXIS 25270, 1997 WL 576504 (Fed. Cir. 1997).

Opinion

RADER, Circuit Judge.

Jack Emert and Robert D. Lundberg (collectively Emert) appeal the rejection of claims 1-5 and 43-67 of application No. 07/250,887 (’887 application). The United States Patent and Trademark Office’s Board of Patent Appeals and Interferences (Board) rejected Emert’s contested claims for obviousness-type double patenting. Recognizing that the Board applied the correct test and reached the proper result under the correct standard of review, this court affirms.

I.

This case arises from an interference between Emert’s ’887 application and Bever-wijk et al.’s U.S. Patent No. 5,873,004. Bev-erwijk conceded that Emert was the first to invent the subject matter of the interference. Rather than claim priority, Beverwijk asserted that obviousness-type double patenting should prevent Emert from gaining a patent. The Administrative Patent Judge denied Beverwijk’s motion for judgment. On appeal, the Board reversed the APJ and rejected Emert’s claims in the absence of a terminal disclaimer. Specifically, the Board held that Emert’s undue delays in prosecution caused the ’624 patent to issue first. Therefore, the Board employed a one-way obviousness analysis comparing the application with the ’624 patent. Under this analysis, the Board denied issuance to Emert’s application. Instead, the Board required Emert to file a terminal disclaimer limiting his patent term.

The application and patents involved in this action disclose polymer dispersants. These dispersants, when added to motor oil, keep engines clean by preventing particles from settling on engine surfaces. In July 1985, Emert made the first filing of importance at the United States Patent and Trademark Office (PTO) for this case. At that time, Emert filed an application, assigned to Exxon, that later matured into U.S. Patent No. 4,863,624 (’624 patent). This patent claims:

1. An oil soluble dispersant mixture useful as an additive comprising:

(A) from about 10 to 90 weight percent of a first dispersant comprising (a) a first hydrocarbyl substituted C4 to C10 monounsaturated diearboxylic acid producing material formed by reacting a first olefin polymer of C2 to C10 monoole-fin having a number average molecular weight of about 1500 to 5,000 and a first C4 to C10 monounsaturated acid material, said first acid producing material having an average of 1.05 to 1.25 diearboxylic acid producing moieties, per molecule of said first olefin polymer present in the reaction mixture used to form said first acid producing material, and (b) a first nucleophilic reactant selected from the group consisting of amines, alcohols, amino-alcohols and mixtures thereof; and
(B) from about 90 to 10 weight percent of a second dispersant comprising (a) a second hydrocarbyl substituted C4 to Cx0 monounsaturated diearboxylic acid producing material formed by reacting a second olefin polymer of C2 to Cxo mo-noolefin having a ... number average molecular weight of about 700 to 1150 and a second C4 to Cxo monounsaturated acid material, said acid producing material having an average of 1.2 to 2.0 dicarboxylic acid producing moieties, per molecule of said second olefin polymer present in the reaction mixture used to form said second acid producing material, and (b) a second nucleophilic reactant selected from the group consisting of amines, alcohols, amino-alcohols and mixtures thereof.

In short hand, the ’624 patent claims: “An oil soluble dispersant mixture useful as an additive comprising: [A and B].” Emert added component B to his disclosure as part of a continuation-in-part application filed on September 9,1987. In September 1989, the ’624 patent issued to Emert and two other inventors.

On October 16, 1986, Emert filed the first of a series of applications, also assigned to Exxon, that became the contested ’887 application. In July 1987, the PTO rejected all *1460 claims of this first application for obviousness. Rather than respond to the obviousness rejection, Emert waited six months— the maximum period — then abandoned that first application and filed a substantially identical continuation application. Again, in March 1988, the PTO rejected this continuation for obviousness. Again Emert did not respond to the merits of the rejection, but waited the maximum six-month period and filed still another continuation. This second continuation — the ’887 application — was again substantially identical to the original filing.

In November 1988, the examiner determined that the ’887 application contained multiple inventions and imposed a restriction requirement. Emert responded to the restriction requirement on May 11, 1989. On July 28, 1989, the examiner rejected Emert’s elected claims for obviousness. Emert finally responded to the merits on February 1, 1990. This action later ensued. The ’887 application claims:

An oil soluble dispersant useful as an oil additive comprising the product of a reaction mixture comprising:

(a) a hydrocarbyl substituted C4 to Cio monounsaturated dicarboxylie acid producing material formed by reacting olefin polymer of C2 to Cio monoolefin having a number average molecular weight of about 700 to 1200 and a C4 to Cio monounsaturated acid material, said acid producing material having an average of about 1.3 to 1.8 dicarboxylie acid producing moieties, per molecule of said olefin polymer present in the reaction mixture used for forming said acid producing material; and
(b) a nucleophilic reactant selected from the group consisting of amines, amino-alcohols and mixtures thereof.

In short hand, the ’887 application claims: “An oil soluble dispersant useful as an oil additive comprising the product of a reaction mixture comprising: [BJ.” As to the relation between B and Bi, the dispersant claimed in the ’624 patent [B] has a molecular weight of 700—1150 compared with 700—1200 in B4 of the ’887 application. The ’624 patent’s B also has a functionality ratio of 1.2—2.0 compared with 1.3'—1.8 in Bi of the ’887 application. Emert claims that these very slight differences minimize interactions with other oil additives.

On appeal, Emert claims the Board made numerous errors in rejecting the claims for obviousness-type double patenting. First, Emert argues that the Board erred by declining to use a two-way obviousness-type double patenting analysis. Specifically, Emert faults the Board’s finding that his delays slowed the prosecution of his application and caused the ’624 patent to issue ahead of the ’887 application. Second, Emert argues that even under a one-way analysis the Board erred because it did not provide a proper evidentiary basis for the finding of obviousness.

II.

A rejection under the doctrine of double-patenting is a legal conclusion to which this court gives complete and independent review. See In re Goodman, 11 F.3d 1046, 1052, 29 USPQ2d 2010, 2015 (Fed.Cir. 1993). The ultimate determination of whether a one-way or two-way analysis is appropriate is also a question for the court. However, the PTO made factual findings underlying its decision to use a one-way analysis. This court reviews these underlying factual findings for clear error. See In re Caveney,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re CELLECT, LLC
Federal Circuit, 2023
Immunex Corporation v. Sandoz Inc.
964 F.3d 1049 (Federal Circuit, 2020)
Anza Technology, Inc. v. Mushkin, Inc.
934 F.3d 1359 (Federal Circuit, 2019)
In Re Hubbell
709 F.3d 1140 (Federal Circuit, 2013)
In Re Fallaux
564 F.3d 1313 (Federal Circuit, 2009)
In Re Basell Poliolefine Italia S.P.A.
547 F.3d 1371 (Federal Circuit, 2008)
Amgen, Inc. v. F. Hoffmann-La Roche Ltd.
581 F. Supp. 2d 160 (D. Massachusetts, 2008)
Bayer AG v. Dr. Reddy's Laboratories, Ltd.
518 F. Supp. 2d 617 (D. Delaware, 2007)
In Re Metoprolol Succinate Patent Litigation
494 F.3d 1011 (Federal Circuit, 2007)
AstraZeneca AB v. KV Pharmaceutical Co.
494 F.3d 1011 (Federal Circuit, 2007)
In Re Glaxo '845 Patent Litigation
450 F. Supp. 2d 435 (S.D. New York, 2006)
Eli Lilly & Co. v. Zenith Goldline Pharmaceuticals, Inc.
364 F. Supp. 2d 820 (S.D. Indiana, 2005)
Engineered Products Co. v. Donaldson Co., Inc.
225 F. Supp. 2d 1069 (N.D. Iowa, 2002)
Geneva Pharmaceuticals, Inc. v. Glaxosmithkline PLC
213 F. Supp. 2d 597 (E.D. Virginia, 2002)
In re Berg
140 F.3d 1428 (Federal Circuit, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
124 F.3d 1458, 44 U.S.P.Q. 2d (BNA) 1149, 1997 U.S. App. LEXIS 25270, 1997 WL 576504, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-jack-emert-and-robert-d-lundberg-cafc-1997.